stable angina pectoris of coronary heart disease
Conditions
Interventions
treatment group:Accept Yangxin Shengmai Granules, 1 bag each time, 3 times a day
control group:Accept the Yangxin Shengmai Granule Simulator, 1 bag each time, 3 times a day.
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of Western medicine for stable angina pectoris of coronary heart disease; 2. Traditional Chinese medicine differentiation is characterized by deficiency of both qi and yin; 3. 30-75 years old (including 30 and 75 years old), regardless of gender; 4. The patient or their legal representative signs an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with acute myocardial infarction, unstable angina, stable exertion angina, grade IV, and other heart diseases; 2. Patients with hypertension and diabetes under poor control, severe cardiopulmonary insufficiency, severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc.), who have used cardiac pacemaker and Cerebrovascular disease within one year; 3. During the screening period, there is a history or evidence of any of the following diseases: Severe cardio cerebral Vascular disease Active, recurrent peptic ulcer or other bleeding related diseases Other serious digestive system diseases Merging malignant tumors, hematological diseases, or other serious or progressive systemic diseases Patients who are unable or unwilling to cooperate due to the merger of other mental illnesses 4. Any laboratory test indicator that meets the following standards before screening: Indication of liver and kidney function upon admission: ALT, AST>1.5 times the upper limit of normal value, Cr>1.2 times the upper limit of normal value (refer to the range of normal values in the laboratory of the research center where the patient is located), other clinically significant laboratory test abnormalities, and the situation where the researcher determines that admission is not suitable 5. Suspect or have a history of alcohol or drug abuse; 6. Pregnant, lactating women or those who have recently planned pregnancy and are unwilling to use contraception; 7. Patients who have participated in clinical trials of other drugs within the first 3 months of enrollment; 8. Researchers believe that patients should not participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The withdrawal rate of Nitroglycerin tablets after 4 weeks of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in angina symptom score from baseline after 2 and 4 weeks of treatment;Evaluation of clinical outcomes reported by patients with coronary heart disease and angina pectoris after 2 and 4 weeks of treatment (CHD-PRO); | — |
Countries
China
Contacts
Public ContactLi Jun
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed